This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
View Post 5 min This content is machine translated Metabolic Dysfunction-Associated Steatotic Liver Disease Cardiology and hepatology in one boat Metabolic dysfunction has far-reaching negative effects on the body, which can manifest as cardiovascular and liver disease. Traditionally, these conditions have been treated in an organ-centered manner, resulting in isolated…
View Post 6 min This content is machine translated Obesity therapy Why lifestyle modification alone is not effective According to current understanding, obesity is considered a multifactorial chronic disease. The overriding goals of treatment are to improve the general state of health and weight-associated diseases or risk factors.…
View Post 5 min This content is machine translated Obesity The pounds tumble under incretin-based therapies Antiadiposita can effectively support the success of lifestyle interventions and thus close a treatment gap. In Switzerland, the GLP-1 RAs liraglutide and semaglutide are currently the most effective in the…
View Post 5 min This content is machine translated Obesity GLP-1-based drugs close the treatment gap The WHO has declared obesity to be a global health problem and weight reduction is an important measure in the prevention and treatment of metabolic diseases such as type 2…
View Post 6 min This content is machine translated Incretin-based therapies for type 2 diabetes Evolution of therapy options continues Incretin mimetics are an attractive treatment option, particularly for the subgroup of overweight type 2 diabetics, as they not only have glucose-lowering effects, but have also demonstrated clinical benefits in…
View Post 4 min This content is machine translated Renal effects of empagliflozin Combination with semaglutide does not reduce albuminuria more than Empa mono SGLT2 inhibitors and GLP1 receptor agonists (GLP1-RA) are antidiabetic drugs with the potential to preserve kidney function. Their different mechanisms of action suggest that combination therapy could have additive or…
View Post 3 min This content is machine translated Type 2 diabetes: PIONEER REAL Switzerland study Semaglutide in oral form convinces in everyday practice In the non-interventional PIONEER REAL Switzerland study, adult type 2 diabetics treated with oral semaglutide as part of routine clinical care achieved clinically significant improvement in glycemic control with no…
View Post 10 min This content is machine translated GLP-1 agonists continue to gain ground Semaglutide in patients with obesity and heart failure It has long been known that the active ingredient class of glucagon-like peptide-1 agonists (GLP-1) reduces cardiovascular consequences in diabetics and leads to significant weight loss in patients with obesity.…
View Post 3 min This content is machine translated GLP-1-RA and dual GLP-1/GIP agonists. Tackling obesity – not only diabetics benefit from the effects While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but…
View Post 5 min This content is machine translated Findings from the SUSTAIN-6 study GLP-1RA with cardiovascular benefits in the treatment of type 2 diabetes In the context of prevalent type 2 diabetes (T2D) worldwide and associated comorbid cardiovascular disease, the results of the SUSTAIN-6 trial add to the accumulating evidence of robust cardiovascular risk…
